Patent Opposition Database

Hide annotations

Related patent application (please put in national patent application/publication number or PCT application/publication number): AR109064A2
Who filed: CILFA
Country: Argentina
Opposition type: Pre-Grant
Opposition status: Under Examination
Date: 07-02-2019
Patent type: Formulations

Click within the document, or manually enter the page number below

CILFA opposition, dapagliflozin-empagliflozin-insulin, (AR112015A1)

Countries: Argentina Date: 2019
CILFA opposition, rosuvastatin, (P000100408)

Countries: Argentina Date: 2002
CILFA opposition, benzoilguanidinas (Markush), (P990106043)

Countries: Argentina Date: 2003
CILFA opposition, semaglutide, (AR114353A1)

Countries: Argentina Date: 2021
CILFA opposition, LIXISENATIDE, (AR103415A1)

Countries: Argentina Date: 2017
CILFA opposition, Insulin LysB3 Glu B29, (AR096376A2)

Countries: Argentina Date: 2016
CILFA opposition, insulin analogues / derivatives, (AR095114A1)

Countries: Argentina Date: 2016
CILFA opposition, botulinum toxin A, (AR112121A1)

Countries: Argentina Date: 2019
CILFA opposition, cariprazine, (AR112137A1)

Countries: Argentina Date: 2019
CILFA opposition, buprenorphine, (AR110468A1)

Countries: Argentina Date: 2019

Cilfa Opposition, Trelagliptin, (Ar109064 A2)